Viewing Study NCT06415461


Ignite Creation Date: 2025-12-24 @ 12:53 PM
Ignite Modification Date: 2026-02-11 @ 3:19 PM
Study NCT ID: NCT06415461
Status: RECRUITING
Last Update Posted: 2025-07-18
First Post: 2023-05-26
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)
Sponsor: University of Florida
Organization:

Study Overview

Official Title: A Phase 1, Open Label Dose-Ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of CFL001 Cord Blood Product in Patients With Symptomatic Sacroiliac Joint Syndrome
Status: RECRUITING
Status Verified Date: 2025-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SIJ
Brief Summary: This is a Phase 1 trial. The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001), which, other than specific modifications in manufacturing to render it compatible with current Good Manufacuring Practice (cGMP), is essentially similar to that reported in real-world experience.
Detailed Description: The Phase 1 trial will enroll three subjects into an initial group receiving a low dose of CFL001. Provided that these subjects tolerate this dose well, will proceed to enroll three subjects into a group receiving a middle dose of CFL001. Provided that these subjects tolerate this dose well, will proceed to enroll three subjects into a group receiving the highest dose of CFL001.

All subjects will have Symptomatic Sacroiliac Joint (SIJ) syndrome, with clinical average pain score in the month prior to enrollment ≥50 and ≤90 on a 100-point scale.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: